Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...

Attribution (BY): Credit must be given to the creator. Immunoreagents, most commonly antibodies, are integral components of lateral flow immunoassays. However, the use of antibodies comes with ...

The variable domain gene usage was diverse in these monoclonal antibodies. SAN DIEGO — An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha ...

The Dren Bio therapy is part of a growing trend of research into autoimmune disease medicines that can reset the immune system instead of suppressing it. The work is built on promising results in ...

Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA" report has been added to ResearchAndMarkets.com's ...

Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA" report has been added to ResearchAndMarkets ...

Overall survival: the time a patient lives, regardless of disease stats. Antibody-drug conjugates, as defined by the National Cancer Institute, are comprised of a monoclonal antibody chemically linked ...

Get Instant Summarized Text (Gist) Lecanemab, an Alzheimer's-modifying drug, has shown a 27% reduction in cognitive decline overall in its Phase 3 trial. However, data indicates it may be less ...